EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Examining the effects of varenicline and naltrexone on delay discounting among individuals with alcohol use disorder

Steven J Nieto iD, James MacKillop iD, Wave-Ananda Baskerville, Annabel Kady, Alicia Izquierdo iD, Lara A Ray iD

Alcohol and Alcoholism · 2025

DOI: 10.1093/alcalc/agaf060 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alcohol and Alcoholism, 2025. Verfasst von Steven J Nieto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of California at Los Angeles, 1285 Franz Hall, Los Angeles, CA 90095, United States. Hauptthemen laut MEDLINE: Varenicline, Naltrexone, Delay Discounting, Alcoholism. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, UCLA RCMAR/CHIME NIA, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Individuals with alcohol use disorder (AUD) often exhibit heightened delay discounting, a behavioral marker associated with poor treatment outcomes. Medications such as naltrexone and varenicline influence reward-related decision-making, but their effects on delay discounting remain unclear. This study examined whether these medications influence delay discounting rates.

Methods

We conducted a double-blind, randomized, placebo-controlled trial in 34 treatment-seeking adults with AUD. Participants were assigned to naltrexone (50 mg/day), varenicline (2 mg/day), or placebo and completed a two-week medication titration followed by a six-day quit attempt. Delay discounting was assessed at baseline and post-treatment using the Monetary Choice Questionnaire (MCQ). General linear models tested medication effects on post-treatment discounting, controlling for baseline discounting, education, and income.

Results

A significant interaction between medication and baseline delay discounting emerged (P = .03; η2 = .67). Among participants with lower baseline discounting, naltrexone reduced delay discounting compared to placebo and varenicline. However, no significant effects were observed in participants with higher baseline discounting. Varenicline did not significantly alter delay discounting compared to placebo.

Conclusions

These findings suggest that naltrexone may reduce delay discounting in individuals with AUD, but primarily among those with lower discounting rates. The results highlight the importance of baseline traits in understanding medication effects on decision-making. Given the small sample size, future research should replicate these findings in larger trials and explore whether delay discounting could serve as a biomarker for personalized AUD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VareniclineNaltrexoneDelay DiscountingAlcoholismNarcotic AntagonistsHumansMaleFemaleDouble-Blind MethodAdultMiddle Aged

Stichwörter der Autor:innen

alcohol use disorderbehavioral economicsdelay discountingimpulsivitynaltrexone

Substanzen

VareniclineNaltrexoneNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Psychology, University of California at Los Angeles, 1285 Franz Hall, Los Angeles, CA 90095, United States.
  • Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, 3901 Chrysler Service Drive, Detroit, MI 48201, United States.
  • Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, 675 Charles E. Young Drive South, Los Angeles, CA 90095, United States.

ORCID-Profile: Steven J Nieto, James MacKillop, Alicia Izquierdo, Lara A Ray

Förderung

  • NIAAA NIH HHS
  • UCLA RCMAR/CHIME NIA
  • NIA NIH HHS
  • NCATS NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute on Aging
  • NCATS

Zitieren

APA

Nieto, S. J., MacKillop, J., Baskerville, W. A., Kady, A., Izquierdo, A., & Ray, L. A. (2025). Examining the effects of varenicline and naltrexone on delay discounting among individuals with alcohol use disorder. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agaf060

Vancouver

Nieto SJ, MacKillop J, Baskerville WA, Kady A, Izquierdo A, Ray LA. Examining the effects of varenicline and naltrexone on delay discounting among individuals with alcohol use disorder. Alcohol and Alcoholism. 2025. doi:10.1093/alcalc/agaf060

BibTeX
@article{Nieto2025,
  author = {Nieto, Steven J and MacKillop, James and Baskerville, Wave-Ananda and Kady, Annabel and Izquierdo, Alicia and Ray, Lara A},
  title = {Examining the effects of varenicline and naltrexone on delay discounting among individuals with alcohol use disorder},
  journal = {Alcohol and Alcoholism},
  year = {2025},
  doi = {10.1093/alcalc/agaf060}
}
Kostenlos starten →